This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mahdy, A. M.
Right arrow Articles by Webster, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mahdy, A. M.
Right arrow Articles by Webster, N. R.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, April 2006, p. 492-495, Vol. 13, No. 4
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.4.492-495.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Production of Soluble Triggering Receptor Expressed on Myeloid Cells by Lipopolysaccharide-Stimulated Human Neutrophils Involves De Novo Protein Synthesis

Amr M. Mahdy,* Damon A. Lowes, Helen F. Galley, Jane E. Bruce, and Nigel R. Webster

Academic Unit of Anaesthesia and Intensive Care, School of Medicine, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom

Received 2 November 2005/ Returned for modification 21 December 2005/ Accepted 24 January 2006

The triggering receptor expressed on myeloid cells (TREM-1) is a recently identified receptor expressed on neutrophils and monocytes. Activation of the receptor induces neutrophils to release the enzyme myeloperoxidase and inflammatory cytokines such as interleukin-8. TREM-1 has an alternatively spliced variant that lacks the transmembrane region, resulting in the receptor being secreted in a soluble form (sTREM-1). Soluble TREM-1 has been detected in plasma during experimental and clinical sepsis and has been advocated as a diagnostic marker of infection for pneumonia and as a prognostic marker for patients with septic shock. We studied TREM-1 surface expression, using flow cytometry, and simultaneously measured sTREM-1 concentrations in culture supernatants of lipopolysaccharide (LPS)-stimulated neutrophils. TREM-1 surface expression was constitutive and was not upregulated upon LPS stimulation. However, sTREM-1 release from neutrophils was significantly upregulated by LPS stimulation (P < 0.0001), an effect that was abrogated by cycloheximide. Soluble TREM-1 is therefore secreted by human neutrophils in response to LPS challenge in a process involving de novo protein synthesis that is not accompanied by an upregulation of the TREM-1 receptor on the surfaces of the cells.

* Corresponding author. Mailing address: Academic Unit of Anaesthesia & Intensive Care, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, United Kingdom. Phone: (0)1224 553019. Fax: (0)1224 555766. E-mail: a.mahdy{at}abdn.ac.uk.

Clinical and Vaccine Immunology, April 2006, p. 492-495, Vol. 13, No. 4
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.4.492-495.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»